District Court Decision Affirmed in U S Lovenox R enoxaparin sodium Patent Infringement Case: related news

U.S. Patent Office allows another significant VNUS patent

Add our medical news to digg - U.S. Patent Office allows another significant VNUS patent Add our medical news to NewsVine - U.S. Patent Office allows another significant VNUS patent Add our medical news to Fark - U.S. Patent Office allows another significant VNUS patent Add our medical news to Furl - U.S. Patent Office allows another significant VNUS patent Add our medical news to Shadows - U.S. Patent Office allows another significant VNUS patent Add our medical news to YahooMyWeb - U.S. Patent Office allows another significant VNUS patent Add our medical news to Reddit -U.S. Patent Office allows another significant VNUS patent Add our medical news to StumbleUpon - U.S. Patent Office allows another significant VNUS patent Add our medical news to Facebook - U.

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms...

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms Validity of NICE's Patent RA'ANANA, Israel, May 26 /PRNewswire-FirstCall/ -- NICE Systems (NASDAQ: NICE) announced today that in a patent infringement case brought against Verint Americas, Inc. (formerly Witness Systems, Inc.) in the Federal District Court for Northern Georgia in Atlanta, the court found that certain Witness products, which were named in this case, do not infringe NICE's VoIP patent 6871229. NICE intends to appeal this decision. The court rejected Verint's claims challenging the validity of NICE's patent and reaffirmed its validity. The US Patent Office has also, prior to the trial, denied Verint's request for re-examination of the same patent.

District Court Decision Affirmed in U.S. Lovenox(R) (enoxaparin sodium) Patent Infringement Case

PRNewswire-FirstCall/ -- Sanofi-aventis announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the

febit receives U.S. patent for microfluidic extraction method

Add our medical news to digg - febit receives U.S. patent for microfluidic extraction method Add our medical news to NewsVine - febit receives U.S. patent for microfluidic extraction method Add our medical news to Fark - febit receives U.S. patent for microfluidic extraction method Add our medical news to Furl - febit receives U.S. patent for microfluidic extraction method Add our medical news to Shadows - febit receives U.S. patent for microfluidic extraction method Add our medical news to YahooMyWeb - febit receives U.S. patent for microfluidic extraction method Add our medical news to Reddit -febit receives U.S. patent for microfluidic extraction method Add our medical news to StumbleUpon - febit receives U.S. patent for microfluidic extraction method Add our medical news to Facebook - febit receives U.

Quanta Decision Illustrates Case Against Specialized Patent Court

I agree with Mike that the Quanta v. LG decision was a big victory for common sense in patent law. I think it's worth taking a step back to note that this is a continuation of the trend that Mike identified last year. This is at least the fourth time in as many years that the Supreme Court has taken a patent law case, and in every case they've overruled a bad decision by the US Court of Appeals for the Federal Circuit, which has jurisdiction over patent appeals. The Federal Circuit has spent the last 15 years making a mess of patent law, and the Supreme Court has finally started to notice and is working to clean up the Federal Circuit's messes. But it's hard because patents are one of a handful of major issues on its docket, whereas the Supreme Court has lots of other subjects it needs to deal with.

Federal legal submissions go online

A o l n p r a f r a y r a d h p b i t l d e e e a c u t o u e t , a c s f t r a p a a c l s i g a d u m t r f o d r t a y u t a i n e e a c u t, a i y o r a d e e a m g s r t s o r w s a n h d y t o n y- e e a R b r M C e l n y s e d y.

NICE Updates on Patent Infringement Litigation Brought Against Verint; Court Reaffirms Validity of NICE's Patent

RA'ANANA, Israel, May 26 /PRNewswire-FirstCall/ -- NICE Systems NICE announced today that in a patent infringement case brought against Verint Americas, Inc. (formerly Witness Systems, Inc.) in the Federal District Court for Northern Georgia in Atlanta, the court found that certain Witness products, which were named in this case, do not infringe NICE's VoIP patent 6871229. NICE intends to appeal this decision.

U.S. Patent on Cytori's Celution System Technology Issued; Celution System Commercialization not Impacted by Recent 6,777,231 Patent Inventorship Decision

SAN DIEGO--(BUSINESS WIRE)--Jun 24, 2008 - U.S. Patent No. 7,390,484 ("the '484 patent") covering Cytori's (NASDAQ:CYTX) Celution(R) System technology was issued today by the United States Patent and Trademark Office. The '484 patent provides Cytori critical market protection for its commercialization of the Celution System in the United States, where the Company is seeking regulatory approval. The '484 patent also protects Cytori's rights to manufacture the Celution Systems in the United States for commercialization into all markets, including Europe and Asia-Pacific, where the device is currently being sold. Other related patent filings are in progress around the globe.

Uniloc Inc. and Macrovision Corporation Agree to Settle Patent Infringement Lawsuits

Irvine, CA (News - Alert) � Uniloc USA Inc., the leader in physical device recognition for protecting intellectual property, networks and personal data, and Macrovision Corporation, today announced that they have settled pending patent lawsuits. Uniloc had sued Macrovision in the United States District Court for the Central District of California, claiming that Macrovision infringed U.S. Patent No. 5,490,216, entitled System for Software Registration. Macrovision had sued Uniloc in the United States District Court for the Northern District of California, claiming that Uniloc infringed U.S. Patent Nos. 6,202,056, entitled Method for Computer Network Operation Providing Basis for Usage Fees, and other patents. The terms of the settlement are confidential.

Hussey, Ponting fight for top spot

Z':>¯^ÌBf­w-É®eW�GÄÓ(f²ËcQÝßoT›©P�W¤=„àJ†rX”þ¨€S¿€u�ï‹ œ± \óº–Réx̘´ˆd ªA=§¡ÒqùÄÄ£–®³w»6°.Ù©©V±Äq×Àz•E€µ¶Kqñð`¿^ =Aå!²úh@�«Q$’À­*v>z¹‹ÿpaSŠc]ˆ°¯éhÚ¤—V[nÜD%Æ2.†râ°÷¥S_¨¶d“ ‘Šp œzÍÖÀêu¨áëe¦Z‡0»IÍj#ñ¤ñôÈJ!d�ÀzO<˜¹
(4­)Rk6¦ša'‘÷䑈0gÉGèpBÈSûH7fò5T}€ª'1ó†5O8ýz Ñ€ÑzÀO ÛBJác­ŒD0ê�3<¤` h·~ÑQ
<üÐÞòá V"­^']±,Ó#\
Ï)h¿Ò$�xßIšµZD›†µgcVëg)Û[9ÛÜ6£gCsQ)²Œ�ûHe-‡ ¥`…`V¾àjN$Í�gõ^šŽäF4¿
vÖâ€Ï j¾â²¾±©u,Êê»%KÐTüš­ æWÿ¤Ø¬4íš6Ffg|ã‹ Lš0S:c»äésv©uݦ¯Kˆf ©mðkï¤èµvX7D*0·uøq,í­ÀÉ«RêñUÁtk2MC©�:¥œ �=Ù.’ka�2Ã};”}«Ï§aTpøÍ~sïàºÝî+mµ‰!ÓnØàÌe×ÆYÜì.Ù%‡±ávA>Kű\eÌü³·Ó¸>hô¡6“O‘ýˆW.;©ølè^Û©íU*MÈØ·8_kÑsÚ6°ï"¿ÁÏ s Nwý×9¨¯TÏ/<æÃÔ““1S°B—´Ù¤«­=·ñ̺G�‘˜ÿ›Ê¼½Ì»‰=aØCœM­Î#©}e“ÍéܦuŠ =1šÕ7‚ôq îá1ò€B(¼¼Ÿ'1¬GãøÁÐVMø�37έ|#¨Ÿä�žé¸u½´qOÿV|P#eì[Ù\¹r´Nš»G7c¼Úr4%¸–lMz´Ã}8 PŸâòas

U.S. Patent Office Allows Another Significant VNUS Patent

SAN JOSE, Calif., May 9 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. today announced that the U.S. Patent & Trademark Office has decided to allow a second continuation patent application related to the patents in the VNUS patent infringement lawsuit against suppliers of endovenous laser products. This comes on the heels of the Patent Office's decision last month to allow VNUS a separate patent application, also filed as a continuation of one of the patents in the lawsuit.

Den-Mat(R) Corp. Wins Patent Infringement Suit on LUMINEERS(R)

U.S. Court of Appeals for the Federal Circuit Affirms U.S. District Court for the Northern District of Illinois Favorable Decision for Veneer Manufacturer

Rapid tooling: EOS claims patent infringement against MCP

EOS GmbH (Electro Optical Systems; Krailling, Germany) has filed a patent-infringement lawsuit against MCP Tooling Technologies Ltd. and MCP-HEK Tooling GmbH. Specifying U.S. Patent No. 5,753,171 in the U.S. District Court in South Carolina, EOS says that MCP has violated an agreement reached with it and Swiss laser-specialist Trumpf, whereby MCP received a license for certain EOS patents, as well as some patent rights from Trumpf covering laser sintering. That license did not, however, extend to the U.S. and Canada. EOS filed the suit on May 8 after MCP announced that its Realizer product would be distributed in the U.S.

U.S. Patent and Trademark Office Grants Re-Examination of Patent 6,881,571 on Behalf of Jivan

Jivan Biologics, Inc. announced today that the United States Patent and Trademark Office has ordered the re-examination of U.S. Patent No. 6,881,571. The serial number for the reexamination is 90/009,017. This patent is the sole subject of the suit ExonHit Therapeutics SA and ExonHit Therapeutics, Inc. filed against Jivan Biologics Inc. on March 12, 2007 in the U.S. District Court, Northern District of California.

U.S. Patent and Trademark Office Grants Re-Examination of Patent 6,881,571 on Behalf of Jivan

LARKSPUR, Calif.--(BUSINESS WIRE)--May 19, 2008--Jivan Biologics, Inc. announced today that the United States Patent and Trademark Office has ordered the re-examination of U.S. Patent No. 6,881,571. The serial number for the reexamination is 90/009,017. This patent is the sole subject of the suit ExonHit Therapeutics SA and ExonHit Therapeutics, Inc. filed against Jivan Biologics Inc. on March 12, 2007 in the U.S. District Court, Northern District of California.

Electrovaya Settles Patent Infringement Case

May 28, 2008 (FinancialWire) Electrovaya Inc. (TSX: EFL) (OTC: EFLVF) (Current Market Cap. US$18.09 Mil.) has settled the patent infringement lawsuit brought against the company and other defendants by Typhoon Touch Technologies Inc. (OTCBB: TYPT) (Current Market Cap. US$217.28 Mil.) and Nova Mobility Systems Inc. for an undisclosed sum representing a royalty payment of at least 20% on past and future sales of its Scribbler Tablet PCs in the United States. Additionally, Electrovaya formally recognized the validity of Typhoon s patents at issue in the litigation and acknowledged infringement of one or more of the patent claims. The complaint was filed by Blank Rome LLP in December of 2007 on behalf of the plaintiffs in the United States District Court, Eastern District of Texas, Tyler Division, Case No.

SCOTUS To Hear Small ISPs' Case Against AT&T

snydeq writes "The US Supreme Court has agreed to hear an antitrust case that alleges AT&T squeezed out small ISPs by charging too much for wholesale access to its phone network. The case, originally brought to US District Court in 2003, had been appealed to the US Court of Appeals for the Ninth Circuit. But AT&T requested the case be heard by the Supreme Court on the grounds that prior conflicting appeals court decisions in this area should be resolved at that level. As part of the case, the Supreme Court will likely also ascertain whether AT&T could be held to violate antitrust law without setting its retail prices below its own cost."

Environmental Control Corporation Acquires Second Canadian Patent

VANCOUVER, BC -- 05/20/08 -- Environmental Control Corporation ("EVCC") (OTCBB: EVCC) -- It is with great pleasure that Environmental Control Corporation ("EVCC") (OTCBB: EVCC) announces the approval of its second Canadian Patent. The Reverse Flow Catalytic Muffler, Canadian Patent # 2,448,648, now accompanies Canadian Patent # 2,448,742 -- The Combined Catalytic Muffler. Other intellectual property currently held by EVCC includes two U.S. Patents: The Reverse Flow Catalytic Muffler (U.S. Patent # 7,018,590) and The Combined Catalytic Muffler (U.S. Patent # 6,622,482); and one pending patent in Europe: the Reverse Flow Catalytic Muffler (Patent Application # 02742591.7). It is anticipated that the European patent application will be approved and registered in the near future.

Orexigen(R) Therapeutics Issued a Key U.S. Patent Covering Composition of Contrave(R) into 2025

Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent Number 7,375,111 with broad claims covering sustained release (SR) compositions of bupropion and naltrexone combined in a single dosage form. These two drugs are the active constituents in Contrave(R), the Company's lead obesity product candidate, now in Phase III clinical trials. Naltrexone SR, a proprietary formulation developed by Orexigen, was designed to improve patient tolerability by altering the pharmacokinetic profile of the original product.

US court reaffirms validity of Nice's patent

Israel-based Nice Systems has announced that in a patent infringement case brought against Verint Americas (formerly Witness Systems) in the Federal District Court for Northern Georgia in Atlanta, the court found that certain Witness products, which were named in this case, do not infringe NICE's VoIP patent 6871229. Nice now intends to appeal this decision.

Verint Prevails in Second Patent Litigation Case Against Nice in

Verint Systems Inc. today announced that the U.S. District Court for the Northern District of Georgia entered a judgment of non-infringement in favor of Verint in a patent lawsuit brought by Nice Systems. In a bench trial, the honorable Judge Story found that Verint did not infringe the Nice patent (USPN 6,871,229) pertaining to Internet Protocol (IP) recording. This follows an announcement Verint made last week in which a Georgia jury declared valid and awarded the company over $3.3 million in damages for Nice's infringement of Verint's speech analytics patent.

Salix Commences Patent Infringement Litigation Against Novel Laboratories

2008 JUN 8 - (NewsRx.com) -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced that Salix Pharmaceuticals, Inc.; Norgine, B.V. and Norgine Europe, B. V. have filed a lawsuit in the United States District Court for the District of New Jersey against Novel Laboratories, Inc. for infringement of Norgine's patent protecting MOVIPREP(R) (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution). Norgine licensed MOVIPREP to Salix for commercialization in the United States (see also Salix Pharmaceuticals, Ltd.).

Analysis: appeals court unlikely to fix software patent mess

Last Thursday the United States Court of Appeals for the Federal Circuit heard oral arguments in In Re Bilski, one of the most closely-watched patent cases in years. The case concerns a patent application of one Bernie Bilski for "a method for managing the consumption risk costs of a commodity sold by a commodity provider" by engaging in a series of financial transactions. The patent was rejected by the patent office as too abstract, and Mr. Bilski appealed the decision to the courts. The Federal Circuit, which has been under fire for its liberal rules for patenting abstract concepts, decided to use the case as an opportunity to revisit the issue. In its call for amicus briefs, the Federal Circuit explicitly asked for opinions on whether it should reconsider its State Street decision and tighten limits on abstract ideas.

Salix Commences Patent Infringement Litigation Against Novel Laboratories

RALEIGH, N.C.--(BUSINESS WIRE)--May 14, 2008 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Salix Pharmaceuticals, Inc.; Norgine, B.V. and Norgine Europe, B. V. have filed a lawsuit in the United States District Court for the District of New Jersey against Novel Laboratories, Inc. for infringement of Norgine's patent protecting MOVIPREP(R) (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution). Norgine licensed MOVIPREP to Salix for commercialization in the United States.

Search took 0.95 seconds.